Compare CORT & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | IRON |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.0B |
| IPO Year | N/A | N/A |
| Metric | CORT | IRON |
|---|---|---|
| Price | $39.83 | $55.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $114.20 | $110.08 |
| AVG Volume (30 Days) | ★ 1.9M | 674.2K |
| Earning Date | 02-18-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $741,172,000.00 | N/A |
| Revenue This Year | $23.09 | N/A |
| Revenue Next Year | $29.62 | N/A |
| P/E Ratio | $45.76 | ★ N/A |
| Revenue Growth | ★ 17.92 | N/A |
| 52 Week Low | $32.99 | $30.82 |
| 52 Week High | $117.33 | $99.50 |
| Indicator | CORT | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 38.81 | 41.75 |
| Support Level | $38.00 | $70.60 |
| Resistance Level | $41.92 | $83.93 |
| Average True Range (ATR) | 2.02 | 4.09 |
| MACD | 0.93 | -0.51 |
| Stochastic Oscillator | 24.95 | 18.38 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.